Back to search results
NCT07298993

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

Enrolling by Invitation
PHASE4Ages 60+InterventionalTreatment
Weill Medical College of Cornell University
~240 participants
Updated 2026-07-15 on ClinicalTrials.gov
What's tested:Placebo (matching)Beta-blockers

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The Hierarchical Composite Endpoint
Measured over From baseline (day 0) to end of the follow-up phase (day 120)

Conditions

Heart Failure
HFpEF
HFpEF - Heart Failure With Preserved Ejection Fraction

Explore related trials

Heart failure with normal ejection fraction

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Parag Goyal, MD, MSc · PRINCIPAL_INVESTIGATOR · Weill Medical College of Cornell University
  • Andrew Ambrosy, MD, MPH · PRINCIPAL_INVESTIGATOR · Kaiser Permanente

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Prior EF \<50% (i.e., based on the structured data field on transthoracic echocardiogram)
Current anginal symptoms (i.e., based on the Rose Angina single-question screener for angina)
MI (i.e., diagnostic codes) and/or coronary revascularization (i.e., procedure codes) within 3 years
Hospitalization for a primary discharge diagnosis of atrial fibrillation or atrial flutter in the prior 12 months
Other documented reason in the opinion of the treating provider and/or enrolling clinician-investigator 3. Evidence of recent decompensated HF
Hospitalization for a primary discharge diagnosis of HF within the past 30 days
Change in loop diuretic pharmacy prescription in the past 30 days (i.e. pharmacy prescription data) (Note: This definition is based on documented prescription changes and does not include short-term dose adjustments that were verbally communicated to the patient by their provider.) 4. Estimated life expectancy \<6 months (i.e., diagnostic codes) 5. Diagnosed dementia (i.e.., diagnostic codes) 6. Unable to provide informed consent 7. Loss of Kaiser Permanence Northern California Membership

What this trial measures

  • The Hierarchical Composite EndpointFrom baseline (day 0) to end of the follow-up phase (day 120)

    The primary outcome is net benefit, assessed using a hierarchical composite of four patient-centered outcomes: (1) time to death from any cause, (2) time to all-cause hospitalization, (3) ≥ 5-point difference of KCCQ-12 OSS change from baseline, and (4) ≥ 3-point difference in PROMIS Depression T-score change from baseline